Meeting
2020 Gastrointestinal Cancers Symposium
A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).
Authors
Katelyn Mae Atkins
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
Katelyn Mae Atkins , Jun Gong , Mourad Tighiouart , Samuel J. Klempner , Richard Tuli , Veronica Placencio-Hickok , Andrew Eugene Hendifar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Clinical Trial Registration Number
NCT03207724
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr TPS780)
Abstract #
TPS780
Poster Bd #
Q1
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).
First Author: Andrew Eugene Hendifar
Poster
2014 ASCO Annual Meeting
Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2014 Gastrointestinal Cancers Symposium
FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2022 ASCO Annual Meeting
A phase Ib/II study of sotorasib combined with chemotherapy for second-line treatment of KRAS p. G12C–mutated advanced pancreatic cancer.
First Author: Devalingam Mahalingam